MoonLake Immunotherapeutics (MLTX) Competitors $52.92 +2.48 (+4.92%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$53.00 +0.08 (+0.15%) As of 08/1/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MLTX vs. MRNA, RDY, QGEN, VTRS, ASND, BBIO, VRNA, BPMC, LEGN, and ROIVShould you be buying MoonLake Immunotherapeutics stock or one of its competitors? The main competitors of MoonLake Immunotherapeutics include Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Blueprint Medicines (BPMC), Legend Biotech (LEGN), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. MoonLake Immunotherapeutics vs. Its Competitors Moderna Dr. Reddy's Laboratories Qiagen Viatris Ascendis Pharma A/S BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines Legend Biotech Roivant Sciences Moderna (NASDAQ:MRNA) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk. Which has higher earnings and valuation, MRNA or MLTX? MoonLake Immunotherapeutics has lower revenue, but higher earnings than Moderna. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModerna$3.24B3.30-$3.56B-$8.73-3.16MoonLake ImmunotherapeuticsN/AN/A-$118.94M-$2.30-23.01 Which has more volatility & risk, MRNA or MLTX? Moderna has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Do analysts rate MRNA or MLTX? Moderna presently has a consensus target price of $46.11, suggesting a potential upside of 67.07%. MoonLake Immunotherapeutics has a consensus target price of $73.14, suggesting a potential upside of 38.21%. Given Moderna's higher possible upside, equities analysts plainly believe Moderna is more favorable than MoonLake Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moderna 4 Sell rating(s) 17 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04MoonLake Immunotherapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Is MRNA or MLTX more profitable? MoonLake Immunotherapeutics has a net margin of 0.00% compared to Moderna's net margin of -105.67%. Moderna's return on equity of -28.69% beat MoonLake Immunotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Moderna-105.67% -28.69% -21.94% MoonLake Immunotherapeutics N/A -30.81%-28.40% Do institutionals & insiders hold more shares of MRNA or MLTX? 75.3% of Moderna shares are held by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. 11.0% of Moderna shares are held by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media prefer MRNA or MLTX? In the previous week, Moderna had 26 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 40 mentions for Moderna and 14 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.95 beat Moderna's score of 0.26 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 9 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 15 Negative mention(s) 0 Very Negative mention(s) Neutral MoonLake Immunotherapeutics 5 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryModerna and MoonLake Immunotherapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get MoonLake Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MLTX vs. The Competition Export to ExcelMetricMoonLake ImmunotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.23B$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.08%P/E Ratio-23.0117.6228.6723.80Price / SalesN/A179.18373.9066.65Price / CashN/A41.9535.4557.96Price / Book7.468.508.275.55Net Income-$118.94M-$55.06M$3.24B$259.03M7 Day Performance-3.90%-3.98%-3.69%-4.59%1 Month Performance10.57%9.59%4.33%4.46%1 Year Performance28.20%6.72%25.95%18.03% MoonLake Immunotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MLTXMoonLake Immunotherapeutics2.7013 of 5 stars$52.92+4.9%$73.14+38.2%+25.9%$3.23BN/A-23.012News CoverageUpcoming EarningsMRNAModerna4.4709 of 5 stars$33.91-0.7%$46.11+36.0%-70.7%$13.21B$3.14B-3.885,800Trending NewsEarnings ReportAnalyst ForecastOptions VolumeRDYDr. Reddy's Laboratories1.9721 of 5 stars$14.71+0.2%$16.95+15.3%-15.5%$12.25B$3.81B22.2827,811QGENQiagen3.3183 of 5 stars$51.00-1.5%$49.40-3.1%+12.1%$11.51B$1.98B127.875,765News CoverageUpcoming EarningsVTRSViatris2.227 of 5 stars$9.26-1.6%$10.40+12.3%-26.3%$11.04B$14.33B-2.9232,000Upcoming EarningsShort Interest ↑ASNDAscendis Pharma A/S3.0931 of 5 stars$164.16-2.0%$223.07+35.9%+27.8%$10.24B$393.54M-26.141,017Analyst ForecastBBIOBridgeBio Pharma4.7123 of 5 stars$46.23-0.2%$61.50+33.0%+80.9%$8.79B$127.42M-13.10400Upcoming EarningsAnalyst ForecastVRNAVerona Pharma PLC American Depositary Share2.1954 of 5 stars$105.09-0.2%$109.00+3.7%+365.2%$8.54B$118.54M-52.5530Positive NewsUpcoming EarningsShort Interest ↑BPMCBlueprint Medicines1.0661 of 5 stars$129.46flat$128.25-0.9%N/A$8.36B$562.12M-52.41640Upcoming EarningsLEGNLegend Biotech3.5917 of 5 stars$41.51-4.3%$73.33+76.7%-29.5%$7.97B$627.24M-70.352,609Positive NewsROIVRoivant Sciences1.8472 of 5 stars$11.35-1.7%$16.50+45.4%+6.5%$7.85B$29.05M-45.40860Upcoming Earnings Related Companies and Tools Related Companies MRNA Competitors RDY Competitors QGEN Competitors VTRS Competitors ASND Competitors BBIO Competitors VRNA Competitors BPMC Competitors LEGN Competitors ROIV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MLTX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share MoonLake Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
